Determination of urinary enzymes as a marker of early renal damage in diabetic patients

被引:84
作者
Mohammadi-Karakani, Ali [1 ,2 ,3 ]
Asgharzadeh-Haghighi, Solmaz [2 ]
Ghazi-Khansari, Mahmoud [1 ,3 ]
Hosseini, Rohollah
机构
[1] Univ Tehran Med Sci, Sch Med, Dept Pharmacol, Tehran, Iran
[2] Alborz Hosp, Social Secur Org, Karaj, Iran
[3] Univ Tehran Med Sci, Sch Pharm, Dept Toxicol, Tehran, Iran
关键词
diabetic nephropathy; urinary enzymes; urinary NAG excretion; microalbuminuria;
D O I
10.1002/jcla.20212
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Diagnosis of diabetic nelphropathy in the early stages is very important since there are no clinical signs or symptoms. Urinary N-acetyl-beta-D-glucosaminidase (NAG) excretion has been recommended as a tubular dysfunction marker that elevates before other markers, such as microalbuminuria and a decrease in creatinine clearance. In this study, we compared excretion of urinary enzymes with other markers that are used routinely in diabetic nephropathy assessment. Urinary NAG, lactate clehydrogenase (LDH), alkaline phosphatase (AP) activities, urea, creatinine, and albumin, with levels of serum glucose and creatinine and whole blood glycosylated hemoglobin (HbA1c) were measured in 32 diabetes mellitus patients and 25 healthy subjects (controls). Notably, urinary NAG, AP, LDH excretion, and microalbuminuria in the diabetic patients group were significantly increased compared to those in the control groups (P <0.001, P<0.05, P<0.01, and P<0.01, respectively). Meanwhile, our results showed that the urinary NAG excretion had the highest sensitivity and specificity (100% and 87.5%, respectively) compared to other markers. We showed that measuring urinary NAG excretion could be useful for the assessment of renal failure in diabetes mellitus patients and confirmed the use of NAG as a routine screening test.
引用
收藏
页码:413 / 417
页数:5
相关论文
共 26 条
[1]   Urinary N-acetyl B glucosaminidase as an earlier marker of diabetic nephropathy and influence of low-dose perindopril/indapamide combination [J].
Basturk, T ;
Altuntas, Y ;
Kurklu, A ;
Aydin, L ;
Eren, N ;
Unsal, A .
RENAL FAILURE, 2006, 28 (02) :125-128
[2]   URINARY ENZYMES AS BIOMARKERS OF RENAL INJURY IN EXPERIMENTAL NEPHROTOXICITY OF IMMUNOSUPPRESSIVE DRUGS [J].
BURDMANN, EA ;
ANDOH, TF ;
LINDSLEY, J ;
RUSSELL, J ;
BENNETT, WM ;
PORTER, G .
RENAL FAILURE, 1994, 16 (01) :161-168
[3]   URINARY ENZYMES IN ACUTE-RENAL-FAILURE [J].
CHEW, SL ;
LINS, RL ;
DAELEMANS, R ;
NUYTS, GD ;
DEBROE, ME .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1993, 8 (06) :507-511
[4]   Urinary protein and enzyme excretion as markers of tubular damage [J].
D'Amico, G ;
Bazzi, C .
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2003, 12 (06) :639-643
[5]   Diabetic microvascular complications: can patients at risk be identified? A review [J].
Girach, A. ;
Manner, D. ;
Porta, M. .
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2006, 60 (11) :1471-1483
[6]   Markers of diabetic nephropathy [J].
Hong, CY ;
Chia, KS .
JOURNAL OF DIABETES AND ITS COMPLICATIONS, 1998, 12 (01) :43-60
[7]   Urinary protein excretion in Type 2 diabetes with complications [J].
Hong, CY ;
Chia, KS ;
Ling, SL .
JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2000, 14 (05) :259-265
[8]  
Hosseini R, 1997, TOXICOL METHOD, V7, P153
[9]   Diabetic nephropathy [J].
Ibrahim, HAA ;
Vora, JP .
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 13 (02) :239-264
[10]  
JUNG K, 1988, CLIN CHEM, V34, P544